ArcherDX addresses the bottlenecks associated with using NGS in translational research by offering a robust platform for targeted sequencing applications. By combining proprietary Anchored Multiplexed PCR (AMP) chemistry in an easy-to-use, lyophilized format with a powerful bioinformatics platform, ArcherDX technology dramatically enhances genetic mutation identification and discovery.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/22/18 | $35,000,000 | Series A |
Boulder Ventures Longwood Fund PBM Capital Group Peierls Foundation | undisclosed |
